[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-515677-105":59,"doc-detail-515677-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","post-tuberculosis-lung-disease-towards-prevention-diagnosis-and-care","Post-tuberculosis lung disease: towards prevention, diagnosis, and care","","Post-tuberculosis lung disease describes chronic respiratory sequelae after tuberculosis, including parenchymal damage, airway disease, and pulmonary vascular disease, affecting children, adolescents, and adults. About half of pulmonary tuberculosis survivors may experience persistent structural pathology, impaired lung function, or ongoing respiratory symptoms after active disease resolution. These sequelae contribute to adverse outcomes such as persistent symptoms, functional impairment, continued care seeking, and impacts on income and employment. This Review synthesizes recent evidence, identifies epidemiologic and mechanistic gaps, and proposes key research priorities for prevention, diagnosis, and care.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/post-tuberculosis-lung-disease-towards-prevention-diagnosis-and-care/515677/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/post-tuberculosis-lung-disease-towards-prevention-diagnosis-and-care/515677.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-10-06",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is post-tuberculosis lung disease and what does it include?","Question",{"text":113,"@type":114},"It refers to evidence of chronic respiratory abnormality, with or without symptoms attributable to prior tuberculosis. It includes parenchymal damage, airway disease, and pulmonary vascular disease, and may be associated with functional impairment and ongoing respiratory symptoms.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How common is persistent pathology or symptoms after tuberculosis treatment?",{"text":118,"@type":114},"Approximately half of pulmonary tuberculosis survivors are thought to have ongoing structural pathology, lung function impairment, or respiratory symptoms after the resolution of active disease.",{"name":120,"@type":111,"acceptedAnswer":121},"What strategies does the Review emphasize for prevention, diagnosis, and care?",{"text":122,"@type":114},"It summarizes recent data, highlights evidence gaps, and suggests research priorities. Prevention approaches may address upstream social determinants, early diagnosis and treatment, novel regimens, and host-directed therapies, while diagnosis and care must account for disease heterogeneity and the management of secondary complications and recurrent tuberculosis.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},515677,1791442175,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Review  \nLancet Respir Med 2025;  \n13: 460–72  \nPublished Online  \nMarch 21, 2025 [https://doi.org/10.1016/](https://doi.org/10.1016/)[ ](https://doi.org/10.1016/)[S2213-2600](S2213-2600)([24](24))[00429-6](00429-6)  \nNational Heart & Lung Institute, Imperial College London, London, UK  \n(J Meghji PhD); Department of Respiratory Medicine, Imperial College Healthcare NHS Trust, London, UK (J Meghji); Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA (S C Auld MD); Department of Epidemiology and Department of Global Health, Emory University Rollins School of Public Health, Atlanta, GA, USA (S C Auld); Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine atthe University of Pennsylvania, Philadelphia, PA, USA (G P Bisson MD); Instituto Nacional de Saúde, Marracuene, Mozambique (C Khosa PhD); Department of  \nPost-tuberculosis lung disease: towards prevention, diagnosis, and care  \nJamilah Meghji, Sara C Auld, Gregory P Bisson, Celso Khosa, Refiloe Masekela, Neelima Navuluri, Andrea Rachow  \nThere is a growing body of data describing the high burden of respiratory sequelae seen among tuberculosis survivors, including children, adolescents, and adults. This group of sequelae are known as post-tuberculosis lung disease and include parenchymal damage, airway disease, and pulmonary vascular disease. It is thought that approximately half of pulmonary tuberculosis survivors have ongoing structural pathology, lung function impairment, or respiratory symptoms after the resolution of active disease. Post-tuberculosis lung disease has been associated with adverse patient outcomes, including persistent symptoms and functional impairment, ongoing health seeking, and impacts on income and employment. There is still much to understand about the epidemiology and nature of post-tuberculosis lung disease, but in this Review we focus on strategies for prevention, diagnosis, and care to inform the ongoing work of tuberculosis-affected communities, health-care providers, researchers, and policy makers. We summarise recent data, highlight evidence gaps, and suggest key research priorities for those working in the field.  \nIntroduction  \nTuberculosis disease remains a critical cause of morbidity and mortality worldwide, with an estimated 10·8 million incident cases in 2023.1 The treatment success rate for tuberculosis disease continues to improve,1 but emerging data suggest a high burden of residual physical, psychological, and socioeconomic morbidity among tuberculosis survivors, even after treatment completion.2, 3  \nFactors contributing to this morbidity include localised organ damage caused by tuberculosis-associated inflammation and fibrosis; the effects of systemic inflammation;4 the side-effects of anti-tuberculous medication;2 and the  \nbroader socioeconomic effects of tuberculosis disease, including stigma, social isolation, and loss of income and employment.5,6 Modelling studies suggest that almost half of the global morbidity regarding to tuberculosis disease could fall in the post-tuberculosis period.7  \nAlthough the importance of mitigating tuberculosisassociated catastrophic costs was captured in The Global Plan to End TB strategy targets,8 the need for tuberculosis programmes to measure and prevent broader tuberculosis-associated sequelae has not yet been recognised. This Review focuses on post-tuberculosis lung disease as an important consequence of tuberculosis, which is relevant to the long-term wellbeing of pulmonary tuberculosis survivors.3  \nKey messages  \n• People affected by tuberculosis disease face a high burden of physical, psychosocial, and economic sequelae after treatment completion  \n• Post-tuberculosis lung disease is a heterogenous condition that includes residual damage to the airways and parenchyma and can be associated with ongoing respiratory symptoms, functional impairment, and health-seeking after treatment completion  \n• The burden of post-tuberculosis lun","cbCaicZRLlBq0ASC","https://ap.wps.com/l/cbCaicZRLlBq0ASC","pdf",544623,13,"English","# Key messages\n## The burden of post-tuberculosis lung disease\n# Introduction","[{\"question\":\"What is post-tuberculosis lung disease and what does it include?\",\"answer\":\"It refers to evidence of chronic respiratory abnormality, with or without symptoms attributable to prior tuberculosis. It includes parenchymal damage, airway disease, and pulmonary vascular disease, and may be associated with functional impairment and ongoing respiratory symptoms.\"},{\"question\":\"How common is persistent pathology or symptoms after tuberculosis treatment?\",\"answer\":\"Approximately half of pulmonary tuberculosis survivors are thought to have ongoing structural pathology, lung function impairment, or respiratory symptoms after the resolution of active disease.\"},{\"question\":\"What strategies does the Review emphasize for prevention, diagnosis, and care?\",\"answer\":\"It summarizes recent data, highlights evidence gaps, and suggests research priorities. Prevention approaches may address upstream social determinants, early diagnosis and treatment, novel regimens, and host-directed therapies, while diagnosis and care must account for disease heterogeneity and the management of secondary complications and recurrent tuberculosis.\"}]","Post-tuberculosis lung disease: towards prevention, diagnosis, and care | PDF",1791321135,33]